Investigations using samples from congenital neutropenia (CN) patients with and without AML revealed that higher levels of phosphorylated STAT5 and LEF1 were found in CN patients who developed AML subsequently than in CN patients who did not develop AML. This evidence concerns the gene STAT5A and acute myeloid leukemia.